Immatics Announces Full Year 2022 Financial Results and Corporate Update
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash h…
Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financi…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunother…
. - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secur…
. - New investment allows immatics to perform pivotal study with its lead vaccine IMA901 in patients with renal cell ca…
BioRegio STERN Management GmbH honoured the winners of the regional "Science2Start" competition last Thursday evening. T…
febit today announced a restructuring as a consequence of its strategic focus on bloodbased microRNA biomarker discovery…
The international law firm BEITEN BURKHARDT comprehensively advised In-Q-Tel, Inc., Arlington, Virginia, on a strategic…